Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: In vitro and in vivo evaluation

Yin Chih Fu, Tzu Fun Fu, Hung Jen Wang, Che Wei Lin, Gang Hui Lee, Shun Cheng Wu, Chih Kuang Wang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Nanoparticles (NP) that target bone tissue were developed using PLGA-PEG (poly(lactic-co-glycolic acid)-polyethylene glycol) diblock copolymers and bone-targeting moieties based on aspartic acid, (Asp)n(1,3). These NP are expected to enable the transport of hydrophobic drugs. The molecular structures were examined by 1H NMR or identified using mass spectrometry and Fourier transform infrared (FT-IR) spectra. The NP were prepared using the water miscible solvent displacement method, and their size characteristics were evaluated using transmission electron microscopy (TEM) and dynamic light scattering. The bone targeting potential of the NP was evaluated in vitro using hydroxyapatite affinity assays and in vivo using fluorescent imaging in zebrafish and rats. It was confirmed that the average particle size of the NP was <200 nm and that the dendritic Asp3 moiety of the PLGA-PEG-Asp3 NP exhibited the best apatite mineral binding ability. Preliminary findings in vivo bone affinity assays in zebrafish and rats indicated that the PLGA-PEG-ASP3 NP may display increased bone-targeting efficiency compared with other PLGA-PEG-based NP that lack a dendritic Asp3 moiety. These NP may act as a delivery system for hydrophobic drugs, warranting further evaluation of the treatment of bone disease.

Original languageEnglish
Pages (from-to)4583-4596
Number of pages14
JournalActa Biomaterialia
Volume10
Issue number11
DOIs
Publication statusPublished - 2014 Nov 1

Fingerprint

Aspartic Acid
Nanoparticles
Polyethylene glycols
Bone
Bone and Bones
Acids
Zebrafish
Rats
Assays
Milk
polylactic acid-polyglycolic acid copolymer
In Vitro Techniques
Apatites
Bone Diseases
Apatite
Fourier Analysis
Dynamic light scattering
Durapatite
Drug Delivery Systems
Molecular Structure

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biomaterials
  • Biochemistry
  • Biomedical Engineering
  • Molecular Biology

Cite this

Fu, Yin Chih ; Fu, Tzu Fun ; Wang, Hung Jen ; Lin, Che Wei ; Lee, Gang Hui ; Wu, Shun Cheng ; Wang, Chih Kuang. / Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting : In vitro and in vivo evaluation. In: Acta Biomaterialia. 2014 ; Vol. 10, No. 11. pp. 4583-4596.
@article{d27f2091891849cb8a9e047a19f66ac8,
title = "Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: In vitro and in vivo evaluation",
abstract = "Nanoparticles (NP) that target bone tissue were developed using PLGA-PEG (poly(lactic-co-glycolic acid)-polyethylene glycol) diblock copolymers and bone-targeting moieties based on aspartic acid, (Asp)n(1,3). These NP are expected to enable the transport of hydrophobic drugs. The molecular structures were examined by 1H NMR or identified using mass spectrometry and Fourier transform infrared (FT-IR) spectra. The NP were prepared using the water miscible solvent displacement method, and their size characteristics were evaluated using transmission electron microscopy (TEM) and dynamic light scattering. The bone targeting potential of the NP was evaluated in vitro using hydroxyapatite affinity assays and in vivo using fluorescent imaging in zebrafish and rats. It was confirmed that the average particle size of the NP was <200 nm and that the dendritic Asp3 moiety of the PLGA-PEG-Asp3 NP exhibited the best apatite mineral binding ability. Preliminary findings in vivo bone affinity assays in zebrafish and rats indicated that the PLGA-PEG-ASP3 NP may display increased bone-targeting efficiency compared with other PLGA-PEG-based NP that lack a dendritic Asp3 moiety. These NP may act as a delivery system for hydrophobic drugs, warranting further evaluation of the treatment of bone disease.",
author = "Fu, {Yin Chih} and Fu, {Tzu Fun} and Wang, {Hung Jen} and Lin, {Che Wei} and Lee, {Gang Hui} and Wu, {Shun Cheng} and Wang, {Chih Kuang}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.actbio.2014.07.015",
language = "English",
volume = "10",
pages = "4583--4596",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "11",

}

Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting : In vitro and in vivo evaluation. / Fu, Yin Chih; Fu, Tzu Fun; Wang, Hung Jen; Lin, Che Wei; Lee, Gang Hui; Wu, Shun Cheng; Wang, Chih Kuang.

In: Acta Biomaterialia, Vol. 10, No. 11, 01.11.2014, p. 4583-4596.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting

T2 - In vitro and in vivo evaluation

AU - Fu, Yin Chih

AU - Fu, Tzu Fun

AU - Wang, Hung Jen

AU - Lin, Che Wei

AU - Lee, Gang Hui

AU - Wu, Shun Cheng

AU - Wang, Chih Kuang

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Nanoparticles (NP) that target bone tissue were developed using PLGA-PEG (poly(lactic-co-glycolic acid)-polyethylene glycol) diblock copolymers and bone-targeting moieties based on aspartic acid, (Asp)n(1,3). These NP are expected to enable the transport of hydrophobic drugs. The molecular structures were examined by 1H NMR or identified using mass spectrometry and Fourier transform infrared (FT-IR) spectra. The NP were prepared using the water miscible solvent displacement method, and their size characteristics were evaluated using transmission electron microscopy (TEM) and dynamic light scattering. The bone targeting potential of the NP was evaluated in vitro using hydroxyapatite affinity assays and in vivo using fluorescent imaging in zebrafish and rats. It was confirmed that the average particle size of the NP was <200 nm and that the dendritic Asp3 moiety of the PLGA-PEG-Asp3 NP exhibited the best apatite mineral binding ability. Preliminary findings in vivo bone affinity assays in zebrafish and rats indicated that the PLGA-PEG-ASP3 NP may display increased bone-targeting efficiency compared with other PLGA-PEG-based NP that lack a dendritic Asp3 moiety. These NP may act as a delivery system for hydrophobic drugs, warranting further evaluation of the treatment of bone disease.

AB - Nanoparticles (NP) that target bone tissue were developed using PLGA-PEG (poly(lactic-co-glycolic acid)-polyethylene glycol) diblock copolymers and bone-targeting moieties based on aspartic acid, (Asp)n(1,3). These NP are expected to enable the transport of hydrophobic drugs. The molecular structures were examined by 1H NMR or identified using mass spectrometry and Fourier transform infrared (FT-IR) spectra. The NP were prepared using the water miscible solvent displacement method, and their size characteristics were evaluated using transmission electron microscopy (TEM) and dynamic light scattering. The bone targeting potential of the NP was evaluated in vitro using hydroxyapatite affinity assays and in vivo using fluorescent imaging in zebrafish and rats. It was confirmed that the average particle size of the NP was <200 nm and that the dendritic Asp3 moiety of the PLGA-PEG-Asp3 NP exhibited the best apatite mineral binding ability. Preliminary findings in vivo bone affinity assays in zebrafish and rats indicated that the PLGA-PEG-ASP3 NP may display increased bone-targeting efficiency compared with other PLGA-PEG-based NP that lack a dendritic Asp3 moiety. These NP may act as a delivery system for hydrophobic drugs, warranting further evaluation of the treatment of bone disease.

UR - http://www.scopus.com/inward/record.url?scp=84908134568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908134568&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2014.07.015

DO - 10.1016/j.actbio.2014.07.015

M3 - Article

C2 - 25050775

AN - SCOPUS:84908134568

VL - 10

SP - 4583

EP - 4596

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 11

ER -